NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
08 September 2023 - 1:00PM
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the
“Company”) today issued the following statement regarding the
Schedule 13D filed with the U.S. Securities and Exchange Commission
on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their
subsequent press release issued on September 6, 2023.
“The NeuBase Board of
Directors (“Board”) appreciates input from its shareholders. The
Board remains committed to completing its comprehensive exploration
of strategic alternatives focused on maximizing shareholder value.
The Board does not believe that shareholder value will be enhanced
by issuing the special $1 per share dividend Symetryx requested in
their press release. The Board and management will continue to seek
an open and active dialogue with its shareholders, including
Symetryx.”
Use of Forward-Looking
Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act. These forward-looking statements are distinguished by
the use of words such as “will,” “would,” “anticipate,” “expect,”
“believe,” “designed,” “plan,” “project,” or “intend,” the negative
of these terms, and similar references to future periods. These
forward-looking statements include, without limitation, statements
relating to our conducting a comprehensive evaluation of strategic
alternatives focused on maximizing shareholder value; and
evaluating potential strategic alternatives that may include, but
are not limited to, an acquisition, merger, business combination,
or other transaction and the completion of such a review process.
Any such statements in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
These views involve risks and uncertainties that are difficult to
predict and, accordingly, our actual results may differ materially
from the results discussed in our forward-looking statements. Our
forward-looking statements contained herein speak only as of the
date of this press release. Factors or events that we cannot
predict, including those risk factors contained in our filings with
the U.S. Securities and Exchange Commission (the “SEC”), may cause
our actual results to differ from those expressed in
forward-looking statements. The Company may not actually achieve
the plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Because such statements deal with future events and are
based on the Company's current expectations, they are subject to
various risks and uncertainties, and actual results, performance or
achievements of the Company could differ materially from those
described in or implied by the statements in this press release,
including: risks relating to volatility and uncertainty in the
capital markets for biotechnology and gene therapy companies,
availability of suitable third parties with which to conduct
contemplated strategic transactions, whether we will be able to
pursue a strategic transaction, or whether any transaction, if
pursued, will be completed on attractive terms or at all, whether
our cash resources will be sufficient to fund our foreseeable and
unforeseeable operating expenses and capital requirements, as well
as those risk factors contained in our filings with the SEC. Except
as otherwise required by law, the Company disclaims any intention
or obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new
information, future events or circumstances or otherwise.
NeuBase Investor
Contact:investors@neubasetherapeutics.comNeuBase
Media Contact:media@neubasetherapeutics.com |
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
Von Jun 2023 bis Jun 2024